Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.21 +1.67 (+2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,169,258
Open 65.48
Bid (Size) 63.57 (1)
Ask (Size) 66.30 (1)
Prev. Close 64.54
Today's Range 64.98 - 66.36
52wk Range 53.63 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Oncocyte Reports That Its First-Of-Its-Kind DetermaCNI Blood Test That Tracks Cancer Treatment Progress Could Hit Market By 2023
Image by Nguyễn Hiệp on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
5 Stocks to Buy for the Coming Recession
Each of these stocks to buy are low-beta stocks with attractive dividend yields to help endure a recession. 
Via InvestorPlace

Performance

YTD
+13.55%
+13.55%
1 Month
-1.75%
-1.75%
3 Month
+8.88%
+8.88%
6 Month
+17.08%
+17.08%
1 Year
+15.35%
+15.35%

More News

Read More
AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)
Via Benzinga
AstraZeneca's Combination Inhaler Shines In Phase 3 Asthma Trial
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
From AstraZeneca
Via Business Wire
Biden Says US Ready To Share COVID-19 Vaccine Related Technology
Via Benzinga
White House Says Currently No Plans To Share COVID-19 Shots With North Korea Battling Outbreak
Via Benzinga
Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Via Benzinga
PR Agency Tells Blue-Chip Clients Like AT&T, Coca-Cola, Netflix And More To Avoid Media Inquiries On Abortion Debate
Via Benzinga
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
US Study Shows Omicron As Severe As Previous COVID Variants: Reuters
Via Benzinga
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
From AstraZeneca
Via Business Wire
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
From AstraZeneca
Via Business Wire
FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review
Via Benzinga
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
From AstraZeneca
Via Business Wire
AstraZeneca's Imfinzi/Chemo Combo Goes Under Priority FDA Review For Bile Duct Cancer
Via Benzinga
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Via Viz Release
Exposures COVID-19 Product Safety
Fourth COVID-19 Shot? See Why Medical Professionals Are Skeptical
Via Benzinga
4 Healthcare Funds With "Double Discounts"
Via Talk Markets
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.